Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOSHUA JUNE

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1205147873
CMS profile
282103
Location
LANSING, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$12,423.56

191 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 4 of 4; records 151–191 of 191 matching records. This page contains 41 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOSHUA JUNE

NPI 1205147873 · CMS profile ID 282103

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

LANSING, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–191 of 191 matching records. This page contains 41 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1205147873?year=2025&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOSHUA JUNE, NPI 1205147873, CMS profile ID 282103. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–191 of 191 matching records. This page contains 41 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1205147873?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). JOSHUA JUNE, NPI 1205147873, CMS profile ID 282103. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–191 of 191 matching records. This page contains 41 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1205147873?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
JOSHUA JUNE, NPI 1205147873, CMS profile ID 282103, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–191 of 191 matching records. This page contains 41 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1205147873?year=2025&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

191 matching records · $12,423.56 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 191 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–191 of 191.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
UCB, Inc. $31.5803/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224465512 CMS
Organon LLC $22.3203/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1237670908 CMS
ABBVIE INC. $23.2003/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202142889 CMS
ABBVIE INC. $1.1303/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202142891 CMS
ABBVIE INC. $20.2903/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202142887 CMS
AstraZeneca Pharmaceuticals LP $94.1103/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207090287 CMS
Mallinckrodt Hospital Products Inc. $15.1303/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211973558 CMS
Amgen Inc. $19.7803/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228489991 CMS
Amgen Inc. $17.0003/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228489973 CMS
United Therapeutics Corporation $83.4103/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242547716 CMS
AstraZeneca Pharmaceuticals LP $15.3603/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207193583 CMS
Fresenius Kabi USA, LLC $31.1603/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250519778 CMS
Amgen Inc. $16.4902/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228490009 CMS
ABBVIE INC. $15.8302/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202142885 CMS
ABBVIE INC. $106.8302/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202142883 CMS
Amgen Inc. $13.0502/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227086689 CMS
UCB, Inc. $17.9502/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224465508 CMS
Novartis Pharmaceuticals Corporation $22.5702/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200274446 CMS
Organon LLC $14.6002/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1237670906 CMS
ABBVIE INC. $1.0902/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202142879 CMS
ABBVIE INC. $22.4002/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202142881 CMS
Mallinckrodt Hospital Products Inc. $19.3002/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211973556 CMS
AstraZeneca Pharmaceuticals LP $83.9202/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207221937 CMS
Alexion Pharmaceuticals, Inc. $25.7002/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202940042 CMS
GENZYME CORPORATION $16.1802/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233432530 CMS
Janssen Biotech, Inc. $99.0002/07/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1174840421 CMS
ABBVIE INC. $19.7702/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202142877 CMS
Amgen Inc. $18.0001/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228489975 CMS
Amgen Inc. $19.7801/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228489999 CMS
ABBVIE INC. $24.5501/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202142875 CMS
Amgen Inc. $12.4201/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227086703 CMS
UCB, Inc. $17.5901/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224465506 CMS
ABBVIE INC. $20.2901/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202142873 CMS
ANI Pharmaceuticals, Inc. $100.8001/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248628473 CMS
Amgen Inc. $10.5801/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227086697 CMS
Amgen Inc. $19.3401/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228489993 CMS
AstraZeneca Pharmaceuticals LP $19.8101/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206237101 CMS
Mallinckrodt Hospital Products Inc. $17.0701/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211973554 CMS
Novartis Pharmaceuticals Corporation $27.2701/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200274444 CMS
United Therapeutics Corporation $31.2501/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242549470 CMS
AstraZeneca Pharmaceuticals LP $16.8001/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206993687 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $29,747.50 324
PY2020 $10,174.12 181
PY2021 $7,563.15 235
PY2022 $16,683.44 244
PY2023 $18,533.57 245
PY2024 $14,546.80 207
PY2025 $12,423.56 191

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $12,060.00 2
PY2025 Principal investigator $241,504.19 23
PY2024 Recipient $116,719.00 4
PY2024 Principal investigator $438,062.27 17
PY2023 Recipient $49,622.14 5
PY2023 Principal investigator $117,124.41 38
PY2022 Principal investigator $223,591.16 59
PY2021 Recipient $5,000.00 1
PY2021 Principal investigator $243,279.24 70
PY2020 Recipient $3,568.00 1
PY2020 Principal investigator $342,629.44 86
PY2019 Recipient $54,212.05 7
PY2019 Principal investigator $549,906.46 73

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

25 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,961.15 12/04/2025 Non-covered Recipient Entity
JUNE DO PC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202528136
Principal investigator 1 GlaxoSmithKline, LLC. $1,841.40 11/05/2025 Non-covered Recipient Entity
JOSHUA P JUNE DO PLLC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192153109
Principal investigator 1 ABBVIE INC. $425.40 11/04/2025 Non-covered Recipient Entity
JUNE DO PC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202521199
Principal investigator 1 ABBVIE INC. $2,048.45 10/09/2025 Non-covered Recipient Entity
JUNE DO PC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202516013
Principal investigator 1 GlaxoSmithKline, LLC. $8,577.00 09/10/2025 Non-covered Recipient Entity
JOSHUA P JUNE DO PLLC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192153113
Principal investigator 1 Genentech, Inc. $11,398.00 09/09/2025 Non-covered Recipient Entity
JUNE DO PC
Study to investigate safety and efficiacy of Obinutuzumab in Patients with SLE No dispute reported 06/30/2026 1211619201
Principal investigator 1 ABBVIE INC. $2,224.25 09/03/2025 Non-covered Recipient Entity
JUNE DO PC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202507481
Principal investigator 1 Janssen Research & Development, LLC $1,313.00 08/11/2025 Non-covered Recipient Entity
JUNE DO PC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175358555
Principal investigator 1 ABBVIE INC. $685.50 08/05/2025 Non-covered Recipient Entity
JUNE DO PC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202502062
Principal investigator 1 Amgen Inc. $171.51 07/28/2025 Non-covered Recipient Entity
JUNE DO PC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246643249
Principal investigator 1 ABBVIE INC. $3,600.10 07/02/2025 Non-covered Recipient Entity
JUNE DO PC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202495733
Principal investigator 1 UCB SA $637.95 06/27/2025 Non-covered Recipient Entity
JUNE DO PC
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS No dispute reported 06/30/2026 1246658598
Principal investigator 1 Genentech, Inc. $16,669.00 06/24/2025 Non-covered Recipient Entity
JUNE DO PC
Study to investigate safety and efficiacy of Obinutuzumab in Patients with SLE No dispute reported 06/30/2026 1211619198
Principal investigator 1 ABBVIE INC. $525.60 06/03/2025 Non-covered Recipient Entity
JUNE DO PC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202488935
Recipient Takeda Pharmaceuticals U.S.A., Inc. $4,060.00 05/20/2025 Covered Recipient Physician A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223263084
Principal investigator 1 ABBVIE INC. $848.50 05/06/2025 Non-covered Recipient Entity
JUNE DO PC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202481371
Principal investigator 1 Amgen Inc. $4,258.56 04/28/2025 Non-covered Recipient Entity
JUNE DO PC
P4 Uncontrolled Gout FORWARD II No dispute reported 06/30/2026 1246643258
Principal investigator 1 Janssen Research & Development, LLC $3,340.00 04/28/2025 Non-covered Recipient Entity
JUNE DO PC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175358549
Principal investigator 1 ABBVIE INC. $1,524.95 04/03/2025 Non-covered Recipient Entity
JUNE DO PC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202471972
Principal investigator 1 ABBVIE INC. $2,172.35 03/06/2025 Non-covered Recipient Entity
JUNE DO PC
M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202457397
Recipient Takeda Pharmaceuticals U.S.A., Inc. $8,000.00 02/25/2025 Covered Recipient Physician A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223263082
Principal investigator 1 ABBVIE INC. $849.70 02/05/2025 Non-covered Recipient Entity
JUNE DO PC
M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202444183
Principal investigator 1 Janssen Research & Development, LLC $2,694.00 01/27/2025 Non-covered Recipient Entity
JUNE DO PC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175358542
Principal investigator 1 Amgen Inc. $169,423.67 01/14/2025 Non-covered Recipient Entity
JUNE DO PC
A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants No dispute reported 06/30/2026 1246643253
Principal investigator 1 ABBVIE INC. $4,314.15 01/02/2025 Non-covered Recipient Entity
JUNE DO PC
M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202433832